首页> 外文期刊>BMC Nephrology >Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities
【24h】

Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities

机译:危重病人急性肾损伤的新型介体:通过连续静脉血液滤过处理和抗凝方式的作用

获取原文
           

摘要

Background Novel putative mediators of acute kidney injury (AKI) include immune-cell derived tumour necrosis factor-like weak inducer of apoptosis (TWEAK), angiopoietin-2 (Ang-2) and protein pentraxin-3 (PTX3). The effect of continuous venovenous hemofiltration (CVVH) and different anticoagulation regimens on plasma levels were studied. Methods At 0, 10, 60, 180 and 720?min of CVVH, samples were collected from pre- and postfilter blood and ultrafiltrate. No anticoagulation (n?=?13), unfractionated heparin (n?=?8) or trisodium citrate (n?=?21) were compared. Results Concentrations of TWEAK, Ang-2 and PTX3 were hardly affected by CVVH since the mediators were not (TWEAK, PTX3) or hardly (Ang-2) detectable in ultrafiltrate, indicating negligible clearance by the filter in spite of molecular sizes (TWEAK, PTX3) at or below the cutoff of the membrane. Heparin use, however, was associated with an increase in in- and outlet plasma TWEAK. Conclusion Novel AKI mediators are not cleared nor produced by CVVH. However, heparin anticoagulation increased TWEAK levels in patient’s plasma whereas citrate did not, favouring the latter as anticoagulant in CVVH for AKI.
机译:背景技术新型的急性肾损伤(AKI)假定介体包括免疫细胞衍生的肿瘤坏死因子样细胞凋亡弱诱导物(TWEAK),血管生成素2(Ang-2)和蛋白五环素3(PTX3)。研究了连续静脉血液滤过(CVVH)和不同抗凝方案对血浆水平的影响。方法在CVVH的0、10、60、180和720?min时,分别从过滤前和过滤后的血液和超滤液中收集样品。没有比较抗凝作用(n = 13),普通肝素(n = 8)或柠檬酸三钠(n = 21)。结果TWEAK,Ang-2和PTX3的浓度几乎不受CVVH的影响,因为在超滤液中未检测到介体(TWEAK,PTX3)或几乎没有(Ang-2),这表明尽管分子大小(TWEAK, PTX3)在膜的截止处或以下。然而,肝素的使用与血浆内和血浆血浆TWEAK的增加有关。结论CVVH并未清除或生产新型AKI介体。但是,肝素抗凝可提高患者血浆中的TWEAK水平,而柠檬酸则不能,因此后者在AKI的CVVH中可作为抗凝剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号